Compare · LEVI vs SILO
LEVI vs SILO
Side-by-side comparison of Levi Strauss & Co (LEVI) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEVI and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- LEVI is the larger of the two at $8.12B, about 1788.3x SILO ($4.5M).
- LEVI has been more active in the news (13 items in the past 4 weeks vs 8 for SILO).
- LEVI has more recent analyst coverage (25 ratings vs 0 for SILO).
- Company
- Levi Strauss & Co
- Silo Pharma Inc.
- Price
- -
- -
- Market cap
- $8.12B
- $4.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 0
Levi Strauss & Co
Levi Strauss & Co. operates as an apparel company. It designs, markets, and sells jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories for men, women, and children in the Americas, Europe, and Asia. The company sells its products under the Levi's, Dockers, Signature by Levi Strauss & Co., and Denizen brands; and also licenses its Levi's and Dockers trademarks for various product categories, including footwear, belts, wallets and bags, outerwear, sweaters, dress shirts, kids wear, sleepwear, and hosiery. The company sells its products through third-party retailers, such as department stores, specialty retailers, third-party e-commerce sites, and franchisees who operate brand-dedicated stores; and directly to consumers through various formats, including company-operated mainline and outlet stores, company-operated e-commerce sites, and select shop-in-shops located in department stores and other third-party retail locations. It operates approximately 3,100 brand-dedicated stores and shop-in-shops. The company was founded in 1853 and is headquartered in San Francisco, California.
Latest LEVI
- Levi Strauss & Co filed SEC Form 8-K: Leadership Update
- Director Prime Joshua E was granted 106 shares, increasing direct ownership by 0.14% to 73,422 units (SEC Form 4)
- Director Ming Jenny J was granted 54 shares, increasing direct ownership by 0.07% to 73,087 units (SEC Form 4)
- Director Marberger David S was granted 73 shares, increasing direct ownership by 0.23% to 31,366 units (SEC Form 4)
- Director Geballe Daniel W was granted 130 shares, increasing direct ownership by 0.64% to 20,423 units (SEC Form 4)
- Director Eckert Robert was granted 381 shares, increasing direct ownership by 0.37% to 103,606 units (SEC Form 4)
- Director Garten Yael was granted 156 shares, increasing direct ownership by 0.23% to 69,253 units (SEC Form 4)
- Director Beraud Jill was granted 54 shares, increasing direct ownership by 0.03% to 181,261 units (SEC Form 4)
- Director Patrick Artemis was granted 68 shares, increasing direct ownership by 0.30% to 22,777 units (SEC Form 4)
- Director Jones Jeffrey J Ii was granted 67 shares, increasing direct ownership by 0.64% to 10,590 units (SEC Form 4)
Latest SILO
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
- Silo Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Silo Pharma Inc.
- Silo Pharma Granted European Patent Covering Novel PTSD Therapy
- SEC Form EFFECT filed by Silo Pharma Inc.
- SEC Form 424B3 filed by Silo Pharma Inc.
- Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
- SEC Form S-8 filed by Silo Pharma Inc.
- SEC Form S-3 filed by Silo Pharma Inc.